GUPEA >
Sahlgrenska Academy / Sahlgrenska akademin >
Institute of Neuroscience and Physiology / Inst för neurovetenskap och fysiologi >
Doctoral Theses / Doktorsavhandlingar Institutionen för neurovetenskap och fysiologi >

Mass spectrometric quantification of amyloid-beta in cerebrospinal fluid and plasma


Please use this identifier to cite or link to this item: http://hdl.handle.net/2077/39571

Files in This Item:

File Description SizeFormat
gupea_2077_39571_1.pdfThesis frame1242KbAdobe PDF
View/Open
gupea_2077_39571_2.pdfCover1876KbAdobe PDF
View/Open
gupea_2077_39571_3.pdfAbstract192KbAdobe PDF
View/Open
Title: Mass spectrometric quantification of amyloid-beta in cerebrospinal fluid and plasma
Other Titles: Implications for Alzheimer’s disease
Authors: Pannee, Josef
E-mail: josef.pannee@neuro.gu.se
Issue Date: 7-Oct-2015
University: University of Gothenburg. Sahlgrenska Academy
Institution: Institute of Neuroscience and Physiology. Department of Psychiatry and Neurochemistry
Parts of work: I. Pannee J et al. A selected reaction monitoring (SRM)-based method for absolute quantification of Abeta38, Abeta40, and Abeta42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. J Alzheimers Dis. 2013;33(4):1021-32.
VIEW ARTICLE


II. Leinenbach A et al. Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid. Clin Chem. 2014 Jul;60(7):987-94.
VIEW ARTICLE


III. Pannee J et al. The amyloid-beta degradation pattern in plasma-A possible tool for clinical trials in Alzheimer's disease. Neurosci Lett. 2014 Jun 24;573:7-12.
VIEW ARTICLE


IV. Pannee J et al. Round robin test on quantification of Aβ42 in CSF by mass spectrometry. Alzheimers Dement. 2015 Jul 21;pii S1552-5260(15):02127-5.
VIEW ARTICLE

Date of Defence: 2015-11-06
Disputation: Fredagen den 6 november 2015, kl. 13.00, Hörsal Arvid Carlsson, Academicum, Medicinaregatan 3, Göteborg
Degree: Doctor of Philosophy (Medicine)
Publication type: Doctoral thesis
Keywords: Alzheimer’s Disease
Mass Spectrometry
Biological Markers
Cerebrospinal Fluid
Amyloid beta-Peptides
Abstract: Alzheimer’s disease (AD) is the most common neurodegenerative disease among the elderly and accounts for 60-80% of all cases of dementia. Currently, the diagnosis of AD is based on cognitive tests and mental state exams, but the peptide amyloid-beta (Aβ) in cerebrospinal fluid (CSF) is increasingly used in clinical trials and settings. As for most protein and peptide biomarkers, quantification is performed using antibody-based techniques such as enzyme-linked immunosorbent assay (ELISA). However... more
ISBN: 978-91-628-9488-7 (e-pub)
978-91-628-9487-0 (print)
URI: http://hdl.handle.net/2077/39571
Appears in Collections:Doctoral Theses from Sahlgrenska Academy
Doctoral Theses from University of Gothenburg / Doktorsavhandlingar från Göteborgs universitet
Doctoral Theses / Doktorsavhandlingar Institutionen för neurovetenskap och fysiologi

 

 

© Göteborgs universitet 2011